Pfizer Inc. (NYSE: PFE) observed a decline of -1.86% on Thursday, trading period with closing price of $36.91. The company’s last traded volume of 21360575 shares vs to an average volume of 20482.06K shares. The stock as of last trading session moved at 8.65% from its 52-week low and was trading at -20.57% to its 52-week high.
Pfizer Inc. (PFE) stated financial results for third-quarter 2019 and updated certain components of its 2019 financial guidance.
Financial guidance for Adjusted diluted EPS(3) reflects share repurchases totaling $8.9B already completed in 2019. Dilution related to share-based employee compensation programs is presently predictable to offset the reduction in shares associated with these share repurchases by about half.
- During the first nine months of 2019, Pfizer returned $14.9B directly to shareholders, through a combination of:
– $6.1B of dividends, composed of dividends of $0.36 per share of ordinary stock in each of the first, second and third quarters of 2019; and
– $8.9B of share repurchases, composed of $2.1B of open-market share repurchases in first-quarter 2019 and a $6.8B accelerated share repurchase contract executed in February 2019 and completed in August 2019.
- As of October 29, 2019, Pfizer’s remaining share repurchase authorization was $5.3B.
QUARTERLY FINANCIAL HIGHLIGHTS (Third-Quarter 2019 vs. Third-Quarter 2018)
Third-quarter 2019 revenues totaled $12.7B, a decrease of $618M, or 5%, contrast to the prior-year quarter, reflecting an operational decline of $403M, or 3%, as well as the unfavorable impact of foreign exchange of $215M, or 2%.
Upjohn Revenue Highlights
Third-quarter 2019 Upjohn revenues totaled $2.2B, down 26% operationally, primarily driven by the predictable important volume declines for Lyrica in the U.S.Because of multi-source generic competition that began in July 2019. Not Including the unfavorable impact of Lyrica in the U.S., third-quarter 2019 revenues for Upjohn declined 6% operationally.
Third-quarter 2019 Upjohn revenues in China increased 2% operationally, primarily driven by volume growth for Lipitor and Norvasc in provinces where the volume-based procurement (VBP) program has not yet been implemented as well as operational growth from Viagra, partially offset primarily by volume declines and an unfavorable pricing impact for Lipitor and Norvasc in certain cities where the VBP program was implemented in March 2019. Given 9% operational revenue growth over the first nine months of 2019 and the anticipated expansion of the VBP program to all provinces in China later in 2019, Pfizer now expects Upjohn revenues in China to grow by mid-to-high-single digits operationally for full-year 2019 contrast with 2018.
Analyst recommendation for this stock stands at 2.5. The volatility in the previous week has experienced by 1.57% and observed of 1.38% in the previous month. 74.70% ownership is held by institutional investors while insiders hold ownership of 0.03%. In the trailing 12 months period, return on assets ratio of the Company was 7.20% and return on equity ratio was 18.10% while its return on investment ratio was 10.20%.